Ocrelizumab associates with reduced cerebrospinal fluid B and CD20 CD4 T cells in primary progressive multiple sclerosis.

The anti-CD20 monoclonal antibody ocrelizumab reduces disability progression in primary progressive multiple sclerosis. CD20 is a prototypical B-cell marker; however, subpopulations of CD4 and CD8 T cells in peripheral blood and cerebrospinal fluid also express low levels of CD20 (CD20). Therefore, direct targeting and depletion of these CD20 T-cell subpopulations may contribute to the therapeutic effect of ocrelizumab.

High performance methylated DNA markers for detection of colon adenocarcinoma.

Background: Colon cancer (CC) is treatable if detected in its early stages. Improved CC detection assays that are highly sensitive, specific, and available at point of care are needed. In this study, we systematically selected and tested methylated markers that demonstrate high sensitivity and specificity for detection of CC in tissue and circulating cell-free DNA.